Pembrolizumab plus lenvatinib in recurrent gynaecological clear cell carcinoma (LARA): a multicentre, single-arm, phase 2 trial. - Ngoi NYL; Lee JY; Lim D; Thian YL; Lim YW; Chan JJ; Chay WY; Zhang Z; Gopinathan A; Lim SE; Low J; Ng J; et al. (The Lancet. Oncology, 2026)